Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Trends in Prostate Cancer Care
Prostate cancer experts share exciting changes to the prostate cancer treatment landscape and how we are now better equipped to take care of patients with prostate cancer.
Patient-Healthcare Provider Communication Regarding Challenges
A prostate cancer expert reemphasizes importance of open communication between patients and healthcare providers.
Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC
A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.
In-Class Transition From Bortezomib to Ixazomib in MM: ASH 2021 Update
Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.
Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy
A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.
IRd in Multiple Myeloma: Patient-Reported Adherence and Outcomes
Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers
Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.
Ursula A. Matulonis, MD, Discusses Rationale for Assessing Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
Ursula A. Matulonis, MD, highlights the rationale behind studying mirvetuximab soravtansine (IMGN853) as a therapy for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.
Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial Cancers
Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.
Marina Frimer, MD, Discusses Maintenance Niraparib in Platinum-Sensitive Uterine Serous Cancer
Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.
The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data
Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.
A Physician’s Take on the CLEAR Trial Data
Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.
Exciting Developments in the Pipeline in HER2+ MBC
A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
HER2+ MBC: Radiation Necrosis Vs Disease Progression
Improvements regarding the identification and management of radiation necrosis in patients with HER2-positive metastatic breast cancer.
Presentation and Disease Course of Differentiated Thyroid Cancer
Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.
The Role of Genetic Mutations in Prognosis and Decision-Making
Chung-Han Lee, MD, PhD discusses how genetic mutations inform patient prognosis and decision-making for patients with kidney cancer.
Prognostic Value of Biomarkers in RCC
Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.
Biomarker Testing: Methodologies, Sample Types, and Emerging Data
Mehmet Asim Bilen, MD weighs in on various biomarker testing methodologies, sample considerations, and emerging data on novel biomarkers.
